Evidence map›Paper›PMID 37332355›Full record

ArticleFrontiers in pharmacology2023

Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study.

Shanshan Li, Xiaojie Wu, Nanyang Li, Guoying Cao, Jingjing Wang, Yuancheng Chen, Size Li, Jinjie He, Jufang Wu, Haijing Yang and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Shanshan LiHuashan Worldwide Medical Center, Huashan Hospital, Fudan University, Shanghai, China.
Xiaojie WuPhase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Nanyang LiPhase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Guoying CaoPhase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Jingjing WangPhase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Yuancheng ChenPhase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Size LiPhase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Jinjie HePhase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Jufang WuPhase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Haijing YangPhase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Ke LinDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Chao QiuDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Angela LiuHiFiBiO (Hang Zhou) Ltd., Shanghai, China.
He ZhouHiFiBiO (Hang Zhou) Ltd., Shanghai, China.
Francisco AdrianHiFiBiO (Hang Zhou) Ltd., Shanghai, China.
Liang SchweizerHiFiBiO (Hang Zhou) Ltd., Shanghai, China.
Wenhong ZhangHiFiBiO (Hang Zhou) Ltd., Shanghai, China.
Jingwen GuHuashan Worldwide Medical Center, Huashan Hospital, Fudan University, Shanghai, China.
Jing ZhangPhase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19HFB30132Aimmunogenicitymonoclonal antibodyneutralizing antibodypharmacokineticssafetySARS-CoV-2

Identifiers

PMID37332355
PMCPMC10269516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.